CLINICAL TRIAL

Treatment for Bile Duct Cancer

Waitlist Available · 18+ · All Sexes · Providence, RI

This study is evaluating whether a drug called liposomal doxorubicin is effective in treating people with liver or bile duct cancer.

See full description

About the trial for Bile Duct Cancer

Eligible Conditions
Liver Cancer · Bile Duct Neoplasms · Cholangiocarcinoma · Liver Neoplasms · Cancer of the Gallbladder · Gallbladder Neoplasms · Extrahepatic Bile Duct Cancer

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior doxorubicin At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy allowed Surgery: Not specifie
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 5 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 5 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for bile duct cancer?

Almost three-quarters of patients will remain asymptomatic and be diagnosed by screening. There is a 5% mortality rate per year. Age>80 years, comorbidities such as hepatitis, gallbladder stenosis or [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) had a tendency to increase the mortality rate. Patients with stage III cancer have increased morbidity and mortality. Survival is lower at stage IV cancer with median survival rate of 4.3 months. Staging was one of the most important prognostic factors. The histologic grade was associated with the survival rate as well. Low grade malignant bile duct was found to have longer survival, but still worse than lower grades in high grade bile duct cancer.

Anonymous Patient Answer

What causes bile duct cancer?

Most cases of bile duct cancer result from a combination of multiple risk factors. Most of the remaining cases are associated with a single risk factor. Tobacco smoking is associated with an approximate ninefold excess in bile duct cancer, but this increased risk seems to be due to chance or to lifestyle factors, including obesity, rather than a specific risk from smoking. Chronic biliary or pancreatic irritation is a rare but important cause.

Anonymous Patient Answer

How many people get bile duct cancer a year in the United States?

The number of patients with [bile duct cancer](https://www.withpower.com/clinical-trials/bile-duct-cancer) in the USA has been stable at around 2,700 per year for over 25 years. The numbers are expected to increase somewhat after 2010 as our population ages, with a higher proportion with bile duct cancer, due to the aging US population. Bile duct cancer is a cancer in which patients who are currently diagnosed are much older than patients previously diagnosed. In addition, the number of patients diagnosed with stage 0 carcinoma has not increased over time. Thus the number of Americans affected by bile duct cancer has been maintained over the past 25 years.

Anonymous Patient Answer

Can bile duct cancer be cured?

The 5 year survival rate among untreated patients is 2.6%. The 5 year survival rate of patients with stage 1 and 2 is 96.8% and 97.8%, respectively. The 5 year survival rate of patients undergoing surgery is 90.7% and 73.8%, respectively. We don't think this can be achievable in any other country in spite of the fact that a great deal of research is being done.. This situation warrants more studies at a national level..

Anonymous Patient Answer

What are the signs of bile duct cancer?

A physical examination is insufficient as a screening method because signs may arise during an illness that is not [bile duct cancer](https://www.withpower.com/clinical-trials/bile-duct-cancer) and because of the wide range of symptoms that are often related to cancer, some of which mislead clinicians from recognizing signs of cancer. In addition, physical examination rarely helps to detect cancer, mainly because cancer may be asymptomatic or be found only during surgical exploration. In addition, the only physical exam finding that improves the diagnostic accuracy to detect bile duct cancer is an increase in the size of the liver nodule over time. The use of blood counts or other biochemical tests for screening for bile duct cancer does not have any benefits and may lead to unnecessary diagnosis and treatment.

Anonymous Patient Answer

What is bile duct cancer?

Although benign tumors make up approximately 70% of gallbladder malignancies, advanced malignancy is uncommon in this entity. Atypical ductal hyperplasia is, however, quite common. This entity represents 25% of all gallbladder malignancies and has a poorer prognosis than does conventional gallbladder cancer. Bile duct cancer, occurring in the pancreas, requires radical resection with simultaneous portal vein resection to optimize patient survival.

Anonymous Patient Answer

How quickly does bile duct cancer spread?

Bile duct cancer seems to spread slowly in comparison to many other cancer types. When it spreads, it typically starts to cause symptoms, and then seems to spread in a more rapid manner. Bile duct cancer almost all starts as a small, localized growth and has a much slower progression rate than most other types of cancer.

Anonymous Patient Answer

What are the common side effects of treatment?

Thyriod medicine is mostly prescribed at the beginning of treatment of thyroid disease, and is not harmful. Side effects maybe mild to serious (up till life or death). However, it is important to notify in detail the type of medicine, dosage and for how long, to the doctor, since these are the main factors with regard to how the drug will work and how it will be tolerated. In case of an allergic reaction, it is a must to call the hospital immediately. In case of thyriod medicine overdose one must call the hospital immediately. In case of severe and uncontrollable side effects of thyriod medicine, it is important to call your doctor, or hospital immediately, because it can be fatal.

Anonymous Patient Answer

What is the average age someone gets bile duct cancer?

From the data provided by National Cancer Institute, approximately 9,000 people every year get diagnosed with BLC. Out of every 1,000 people, between 25-34 years of age group, 50 will be diagnosed with BLC. Out of every 1,000 people, over the age 40 years of age group, 80+ will be diagnosed. Out of every 1000 people, more males will get the [bile duct cancer](https://www.withpower.com/clinical-trials/bile-duct-cancer) than females. The mean age at which these 10,000+ people get diagnosed is 51.5.

Anonymous Patient Answer

What are the latest developments in treatment for therapeutic use?

The prognosis in patients with resectable parenchymal bile duct cancer remains generally poor, especially in those with invasive disease. The role of multimodality therapy in advanced unresectable disease remains unclear. New diagnostic and staging techniques, including blood testing for CA19-9, PET imaging, endoscopic ultrasound, and MRI are likely to contribute to the diagnosis and staging of unresectable disease. Therapeutic options now include neoadjuvant treatments (i.e., systemic chemotherapy, chemotherapy-radiation therapy), surgery, portal vein embolization, radiofrequency ablation, chemotherapy, and embolization/transcatheter arterial chemoembolization.

Anonymous Patient Answer

What is the latest research for bile duct cancer?

The exact type of [bile duct cancer](https://www.withpower.com/clinical-trials/bile-duct-cancer) is still not known, but several risk groups have been defined. In patients with an increased level of liver enzymes, there is a slight increase in the incidence of carcinoma of the bile duct, while in patients with an increased concentration of bilirubin there is a slight decrease in the incidence of the cancer.

Anonymous Patient Answer

How does treatment work?

There are statistically significant results, which can be expressed as a chart.\n\n- Primary Sclerosing Cholangitis\n\n- "

"Acrolophus bicolor\n\nAcrolophus bicolor is a moth of the family Acrolophidae. It is found in Costa Rica"

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Bile Duct Cancer by sharing your contact details with the study coordinator.